



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/771,151	01/26/2001	Danilo D. Lasic	55325-8169.US00	9729

7590 01/19/2006

ALZA Corporation
1900 Charleston Road, P.O. Box 7210
M10-3
Mountain View, CA 94039-7210

EXAMINER

KISHORE, GOLLAMUDI S

ART UNIT	PAPER NUMBER
----------	--------------

1615

DATE MAILED: 01/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

MAILED
JAN 19 2006
GROUP 1600

**BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES**

Application Number: 09/771,151
Filing Date: January 26, 2001
Appellant(s): LASIC ET AL.

Michael J. Atkins
For Appellant

EXAMINER'S ANSWER

This is in response to the appeal brief filed 11-3-05 appealing from the Office action
mailed 3-17-04.

(1) Real Party in Interest

A statement identifying by name the real party in interest is contained in the brief.

(2) Related Appeals and Interferences

The statement of the status of claims contained in the brief is correct.

(3) Status of Claims

The statement of the status of claims contained in the brief is correct.

(5) Summary of Claimed Subject Matter

The summary of claimed subject matter contained in the brief is correct.

(7) Claims Appendix

The copy of the appealed claims contained in the Appendix to the brief is correct.

(9) Grounds of Rejection

The following ground(s) of rejection are applicable to the appealed claims:

(9) *Prior Art of Record*

EP 0 551 169	YAMAMOTO et al	7-1993
WO 98/07409	ABRA et al	2-1998
5,013,556	WOODLE et al	5-1991

(10) *Grounds of Rejection*

The following ground(s) of rejection are applicable to the appealed claims:

1. Claims 1, 3-6, 8-9 and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by EP 0 551 169.

EP discloses a method of preparation of liposomes containing a supersaturated solution of a water-soluble drug (note the abstract, Example 3 and claims).

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant argues that Yamamoto et al fails to teach any of steps (ii), (iii) and (iv). These arguments are not found to be persuasive. First of all, it should be noted that applicant recognizes that Yamamoto et al teach that the drug is either saturated or supersaturated state. According to claim 1, these steps are (ii) preparing from a supersaturated solution of the compound liposomes at selected size interval; (iii) analyzing said liposomes for the presence or absence of precipitated compound; (iv) based on said analyzing, selecting liposomes of a size that corresponds to liposomes having no entrapped precipitated compound. Instant claims do not recite what the 'selected size intervals' are in terms of specific sizes. Furthermore, there is no specific definition of the expression in the specification. Yamamoto uses specific population of liposomes (in Example 3 Yamamoto et al teach that the liposome sizes are 100 nm. This implies Yamamoto et al selected liposomes of this size interval meeting the requirement of instant step (ii). The very fact the Yamamoto et al state that the drug is in a supersaturated solution form implies that there is no precipitate (a solution does not contain any precipitate). In example 1 (col. 6), Yamamoto teaches the separation of crystallized cisplatin and the dialysis to remove the crystallized cisplatin (lines 16-21). This implies that Yamamoto et al were monitoring (analyzing) the composition for crystals (precipitate) of the drug thus, meeting the requirement of instant step (iii) since the resulting liposomes of sizes 100 nm do not have the precipitated drug, it is

Art Unit: 1615

construed as their selection of this population of liposomes (instant step (iv)). It should also be pointed out that there is nothing in Yamamoto et al to indicate that the presence or absence of the precipitate was not checked and the very fact Yamamoto et al refers to the drug solution as 'saturated solution or more' implies clearly that there was no precipitate.

2. Claims 1, 3-9 and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by WO 98/07409.

WO 98 discloses a method of preparation of liposomes containing supersaturated solution of an active compound. The liposomes further contain a hydrophilic polymer (PEG) (note the abstract, page 2 line 15 through page 3, line 24, page 6, lines 14-26, page 12, lines 4-21, Example 3 and claims).

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicants' arguments once again pertain to the lack of steps (ii), (iii) and (iv) in the teachings of Abra. These arguments are not found to be persuasive since as with EP, applicants recognize that the reference teaches entrapment of the active agent EITHER in the dissolved or precipitated state. Therefore, the same response as above is applicable.

3. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over EP 0 551 169 in combination with Woodle (5,013,556) of record.

The teachings of EP (Yamamoto) have been discussed above. What is lacking in EP is the inclusion of a hydrophilic polymer in the liposome compositions.

Art Unit: 1615

Woodle discloses that the inclusion of a hydrophilic polymer enhances the circulation time of the liposomes (note the abstract).


The inclusion of a hydrophilic polymer in the liposomes of EP references would have been obvious to one of ordinary skill in the art because it enhances the circulation time of the liposomes as taught by Woodle.

Applicants' arguments have been fully considered but are not found to be persuasive. Although applicants admit that Woodle teaches the use of hydrophilic polymer, they argue that it does not overcome the deficiencies of the primary document. Applicant's arguments with regard to the deficiencies EP references have been addressed above.

Art Unit: 1615

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,


Gollamudi S Kishore, Ph.D
Primary Examiner
Art Unit 1615


GSK
January 12, 2006

Conferees

Thurman Page


THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Jyothsna Venkat, Ph.D


JYOTHSNA VENKAT
PRIMARY EXAMINER
GROUP 1500/600

ALZA Corporation
1900 Charleston Road, P.O. Box 7210
M10-3
Mountain View, CA 94039-7210